Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir
Charlotte Charpentier, Bénédicte Roquebert, Olivier Delelis, Lucile Larrouy, Sophie Matheron, Roland Tubiana, Marina Karmochkine, Xavier Duval, Geneviève Chêne, Alexandre Storto, Gilles Collin, Antoine Bénard, Florence Damond, Jean-François Mouscadet, Françoise Brun-Vézinet, Diane Descamps
Antimicrobial Agents and Chemotherapy 2011, 55 (3): 1293-5
21189351
We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.
Full Text Links
Find Full Text Links for this Article
You are not logged in. Sign Up or Log In to join the discussion.